Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

HIV-1 vaccine development: progress and prospects.

Anna R Thorner1, Dan H Barouch

  • 1Research East Room 213, Division of Viral Pathogenesis,Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA.

Current Infectious Disease Reports
|January 27, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early innate immune signatures correlate with Ad26.COV2.S vaccine durability and protective efficacy.

bioRxiv : the preprint server for biology·2026
Same author

A proteome-wide atlas of humoral immunity to <i>Mycobacterium tuberculosis</i> across the spectrum of disease.

Frontiers in immunology·2026
Same author

Am80-lipid nanoparticles serve as an enteric mucosal adjuvant following parenteral immunization with inactivated polio vaccine.

Science advances·2026
Same author

Safety, pharmacokinetics, and neutralisation activity of PGDM1400LS, VRC07-523LS, and PGT121.414.LS infused intravenously or subcutaneously (HVTN 140/HPTN 101 part B): a phase 1, randomised trial.

The lancet. HIV·2026
Same author

Distinct phases of immune system programming during ART-suppressed immunodeficiency virus infection.

bioRxiv : the preprint server for biology·2026
Same author

Displayed and encoded antigens on adenovirus vectors optimize humoral and cellular immune responses in rhesus macaques.

Journal of virology·2026

Developing an effective HIV-1 vaccine is difficult. Current strategies focus on cellular immunity using DNA or vector vaccines, which are in clinical trials.

Area of Science:

  • Immunology
  • Vaccinology
  • Virology

Background:

  • Developing a prophylactic human immunodeficiency virus type 1 (HIV-1) vaccine remains a global health priority.
  • Eliciting broadly reactive HIV-1-specific neutralizing antibodies has been exceptionally challenging.
  • Current HIV-1 vaccine candidates primarily aim to generate virus-specific cellular immune responses.

Purpose of the Study:

  • To review the progress and prospects of HIV-1 vaccine strategies.
  • To examine the use of plasmid DNA and recombinant live vector vaccines.
  • To discuss their evaluation in advanced clinical trials.

Main Methods:

  • Review of current scientific literature on HIV-1 vaccine development.
  • Analysis of data from plasmid DNA and recombinant live vector vaccine candidates.

Related Experiment Videos

  • Examination of clinical trial outcomes regarding safety, immunogenicity, and efficacy.

    • Main Results:

    • Plasmid DNA and recombinant live vector vaccines can elicit cellular immune responses.
    • These vaccine technologies are currently undergoing advanced phase clinical trials.
    • Challenges remain in developing immunogens for broadly neutralizing antibodies.

    Conclusions:

    • Cellular immune responses are a key focus for current HIV-1 vaccine development.
    • Plasmid DNA and recombinant live vector platforms show promise but require further evaluation.
    • Continued research is essential for advancing HIV-1 vaccine efficacy.